五味子中1個新的聯苯環辛烯類木脂素

邸同蓮，劉小清，吳 楠，陳孝源，范君婷，譚寧華

· 化學成分 ?

五味子中1個新的聯苯環辛烯類木脂素

邸同蓮1，劉小清2，吳 楠1，陳孝源1，范君婷3*，譚寧華1*

1. 中國藥科大學中藥學院，江蘇 南京 211198 2. 揚子江藥業集團北京海燕藥業有限公司，北京 102206 3. 南京醫科大學藥學院，江蘇 南京 211116

研究中藥五味子的木脂素類化學成分。采用硅膠柱色譜、中壓反相柱色譜、半制備和制備液相對五味子中富含木脂素類成分的石油醚萃取部位進行分離、純化，通過波譜數據鑒定化合物的結構。從五味子中分離得到了26個化合物，分別鑒定為綠葉五味子素B（1）、sphaerandrin A（2）、sieverlignan E（3）、arisanschinin G（4）、widdaranal F（5）、戈米辛A（6）、戈米辛B（7）、戈米辛D（8）、戈米辛G（9）、(?)-戈米辛K1（10）、(＋)-戈米辛K2（11）、(?)-戈米辛L1（12）、(＋)-戈米辛M1（13）、戈米辛N（14）、當歸酰戈米辛H（15）、當歸酰戈米辛O（16）、當歸酰戈米辛Q（17）、苯甲酰戈米辛Q（18）、五味子醇甲（19）、五味子甲素（20）、五味子乙素（21）、五味子丙素（22）、五味子酯丙（23）、neglschisandrin E（24）、7(18)-dehydroschisandro A（25）、安五脂素（26），其中24個為聯苯環辛烯類木脂素（1～4、6～25）。化合物1為新化合物，化合物2～5為首次從該植物中分離得到。

五味子；綠葉五味子素B；聯苯環辛烯類木脂素；sphaerandrin A；sieverlignan E；arisanschinin G；widdaranal F；五味子醇甲

五味子為木蘭科植物五味子(Turcz.) Baill.的干燥成熟果實，始載于《神農本草經》，列為上品，習稱“北五味子”，道地產區為黑龍江、吉林、遼寧等地。五味子具有收斂固澀、益氣生津、補腎寧心等功效，可用于治療久咳虛喘、久瀉不止、津傷口渴等癥[1]。五味子中富含木脂素、萜類、揮發油、多糖、酚酸、黃酮、植物甾醇等多類成分，其中木脂素類是其特征活性成分[2]。五味子作為蘇黃止咳膠囊復方中的臣藥，研究發現其木脂素類成分具有舒張氣管平滑肌[3]、抗炎[4-6]、抗纖維化[7-8]、鎮咳平喘[9-11]的功效，可能是該中成藥發揮藥效的活性成分。前期課題組利用LC-MS技術對蘇黃止咳膠囊的化學成分進行分析和藥材溯源，鑒定出300多個化合物[12-13]，其中包含29個木脂素并主要來源于五味子，且研究結果表明五味子醇甲是影響該藥質量的主要成分[14]。因此本實驗研究蘇黃止咳膠囊臣藥五味子的化學成分，有助于進一步闡明蘇黃止咳膠囊的藥效物質基礎及其質量標準研究。

本實驗采用硅膠柱色譜、中壓反相柱色譜、半制備和制備液相對五味子水提物富含木脂素的石油醚萃取部位進行分離純化，共得到25個木脂素和1個倍半萜，包括24個聯苯環辛烯類木脂素（1～4、6～25），分別鑒定為綠葉五味子素B（schiviridin B，1）、sphaerandrin A（2）、sieverlignan E（3）、arisanschinin G（4）、widdaranal F（5）、戈米辛A（gomisin A，6）、戈米辛B（gomisin B，7）、戈米辛D（gomisin D，8）、戈米辛G（gomisin G，9）、(?)-戈米辛K1[(?)-gomisin K1，10]、(＋)-戈米辛K2[(+)-gomisin K2，11]、(?)-戈米辛L1[(?)-gomisin L1，12]、(＋)-戈米辛M1[(+)-gomisin M1，13]、戈米辛N（gomisin N，14）、當歸酰戈米辛H（angeloylgomisin H，15）、當歸酰戈米辛O（angeloylgomisin O，16）、當歸酰戈米辛Q（angeloylgomisin Q，17）、苯甲酰戈米辛Q（benzoylgomisin Q，18）、五味子醇甲（schisandrin，19）、五味子甲素（schisandrin A，20）、五味子乙素（γ-schisandrin，21）、五味子丙素（schisandrin C，22）、五味子酯丙（schisantherin C，23）、neglschisandrin E（24）、7(18)-dehydroschisandro A（25）、安五脂素（anwulignan，26）。其中化合物1為新化合物，化合物2～5為首次從該藥材中分離得到。

1 藥材、儀器與材料

五味子（10 kg）由揚子江藥業集團北京海燕藥業有限公司提供，樣品（ID-210831）保存于中國藥科大學中藥學院譚寧華教授團隊實驗室，經中國藥科大學中藥學院秦民堅教授鑒定為植物五味子(Turcz.) Baill.的干燥成熟果實。

Shimadzu UV-2600i型紫外光譜儀（日本Shimadzu有限公司）；Bruker AV-400型核磁共振儀（德國Bruker公司）；Rudolph Autopl IV型旋光儀（美國Rudolph有限公司）；Bruker Tensor-27型紅外光譜儀（德國Bruker公司）；Japan Jasco J810型圓二光譜儀（日本分光JASCO公司）；Angilent 1260-6230 TOF液質聯用儀（美國Angilent公司）；Waters XevoTQD質譜儀（美國Waters公司）；LC 3000 Ⅰ型制備型HPLC（北京創新通恒科技有限公司）。半制備型液相色譜柱、制備型液相色譜柱以及分析型液相色譜柱分別為YMC-Pack ODS-A C18柱系列（250 mm×10 mm，5 μm，日本YMC公司）、YMC-Pack ODS-A C18柱系列（250 mm×20 mm，5 μm，日本YMC公司）、Waters ACQUITY UPLCHSS T3色譜柱（100 mm×2.1 mm，1.8 μm，美國Waters公司）。柱色譜硅膠（100～200、200～300目）以及GF254薄層板（青島裕明源硅膠試劑廠）；反相材料Lichroprep RP-18（40～63 μm，美國Merck公司）；顯色劑為5%硫酸乙醇溶液；實驗所用試劑均為分析純（無錫市亞盛集團化學試劑有限公司）和色譜純（美國TEDIA公司和Merck公司）；LC-MS級甲酸（德國Sigma-Aldrich公司）。

2 提取與分離

干燥的五味子10 kg，粉碎，用10倍量的水煎煮3次，每次1 h，水提液減壓濃縮得浸膏。浸膏以水溶解，用石油醚、醋酸乙酯、正丁醇依次萃取3～4次，萃取液減壓濃縮得各萃取部位浸膏。各萃取部位浸膏經TLC、LC-MS檢測，確定所需木脂素類成分主要集中在石油醚萃取部位。然后石油醚部位（80.4 g）首先通過硅膠柱色譜（200～300目硅膠），以石油醚-醋酸乙酯（10∶0～0∶10）梯度洗脫，減壓濃縮，TLC、LC-MS檢測合并，得到6個流分（Fr. 1～6）。

Fr. 2（5.936 g）經硅膠柱色譜，以石油醚-醋酸乙酯5個梯度（80∶1、40∶1、20∶1、10∶1、0∶1）進行洗脫，利用TLC和LC-MS檢測，合并獲得7個亞流分（Fr. 2-1～2-7）。Fr. 2-3（473 mg）經反復硅膠柱色譜及制備型HPLC（75%乙腈）純化得到化合物16（34 mg，R＝51.6 min）、22（18 mg，R＝38.8 min）、26（33 mg，R＝23.1 min）。Fr. 2-5（3.7 g）經反復硅膠柱色譜及制備型HPLC（72%乙腈）純化得到化合物14（958 mg，R＝33.0 min）、21（304 mg，R＝35.3 min）。Fr. 3（22.555 g）經硅膠柱色譜，石油醚-醋酸乙酯（50∶1、40∶1、20∶1、10∶1、5∶1、3∶1、0∶1）梯度洗脫，得到9個亞流分（Fr. 3-1～3-9）。Fr. 3-5（5.385 g）經反復硅膠柱色譜及制備型HPLC（60%乙腈）純化得到化合物1（8 mg，R＝33.6 min）、5（56 mg，R＝41.6 min）、10（16 mg，R＝27.6 min）、11（10 mg，R＝24.9 min）、12（19 mg，R＝54.0 min）、13（35 mg，R＝55.8 min）、20（206 mg，R＝29.6 min）、24（22 mg，R＝21.0 min）、25（16 mg，R＝22.5 min）。Fr. 3-7（8.056 g）經反復硅膠柱色譜及制備型HPLC（60%乙腈）純化得到化合物9（24 mg，R＝36.6 min）。Fr. 4（22.91 g）經硅膠柱色譜，石油醚-醋酸乙酯（20∶1、10∶1、5∶1、3∶1、0∶1）梯度洗脫，得到5個亞流分Fr. 4-1～4-5。Fr. 4-2（2.474 g）經制備型HPLC（60%乙腈）純化得到化合物4（6 mg，R＝38.2 min）、6（252 mg，R＝19.1 min）、7（51 mg，R＝34.5 min）、17（217 mg，R＝26.5 min）、23（21 mg，R＝31.4 min）。Fr. 4-3（15.896 g）經RP-18中壓反相柱色譜，甲醇-水（30%～100%）梯度洗脫，利用TLC和LC-MS檢測合并，得到4個亞流分Fr. 4-3-1～4-3-4，其中Fr. 4-3-2（10.202 g）經檢測為化合物19（10.202 g）。Fr. 4-3-3（1.802 g）經制備型HPLC（60%乙腈）純化得到化合物2（15 mg，R＝19.7 min）、3（21 mg，R＝23.8 min）、8（71 mg，R＝15.8 min）、15（608 mg，R＝25.6 min）、18（57 mg，R＝27.1 min）。

3 結構鑒定

化合物1：黃色固體（甲醇），易溶于三氯甲烷。[α]20 D＋82.1°（0.067，MeOH），HR-ESI-MS（/519.197 31 [M＋Na]+；計算值519.198 94），可確定化合物1分子式為C28H32O8，不飽和度為13。紫外光譜顯示其在225 nm處有最大吸收，表明化合物結構中存在較強的共軛系統。紅外光譜在3398、1641、1456、1396、1033 cm?1處有吸收，提示分子中含有苯環、羰基、雙鍵。化合物1的1H-NMR和13C-NMR譜（表1）與schiviridin A[15]較為相似，提示其為聯苯環辛烯類木脂素。

化合物1的1H-NMR譜（表1）顯示2個芳環質子信號H6.73 (1H, s), 6.48 (1H, s)；1個連酯基質子信號H6.42 (1H, s)；1個亞甲二氧基質子信號H5.99 (1H, d,= 1.4 Hz), 5.97 (1H, d,= 1.4 Hz)；2個末端烯氫質子信號H4.83 (1H, s), 4.60 (1H, s)；4個甲氧基質子信號H3.88 (3H, s), 3.84 (3H, s), 3.78 (3H, s), 3.61 (3H, s)；1個次甲基質子信號H2.58 (1H, overlapped)；1個亞甲基質子信號H2.54 (1H, overlapped), 2.24 (1H, dd,= 12.2, 9.6 Hz)；1個甲基質子信號H1.21 (3H, d,= 6.8 Hz)；還具有偶合系統的質子信號H5.95 (1H, m), 1.87 (3H, dq,= 7.2, 1.6 Hz), 1.51 (3H, q,= 1.6 Hz)，結合13C-NMR譜（表1）的酯基碳(C166.3) 和烯碳(C139.6, 127.5)，以及1H-1H COSY譜中H-3/H-4相關信號，可以推導為當歸酰基信號。13C-NMR結合HSQC譜顯示化合物1中有28個碳信號，包括4個甲氧基、3個甲基、1個亞甲二氧基、2個亞甲基、5個次甲基、12個季碳、1個酯基。

表1 化合物1的1H-NMR和13C-NMR數據(400/100 MHz, CDCl3)

1H-1H COSY譜中（圖1），H-8與H-9、H-17相關，表明C-8、C-9、C-17相連。HMBC譜中（圖1）顯示，H-6 (H6.42) 與C-4、C-5、C-7、C-8、C-16、C-18、C-1相關；H-9 (H2.24, 2.54) 與C-11、C-8、C-10、C-15、C-7存在相關信號；芳環H-4 (H6.73) 與C-2、C-3、C-16相關，芳環氫H-11 (H6.48) 與C-12、C-13、C-15相關；這些相關信號提示含有聯苯環辛烯類木脂素的基本骨架。其中，H-6與C-1存在相關信號，表明C-6位是當歸酰基取代；H-6還與C-18相關，顯示末端烯鍵連接在C-7位；亞甲二氧基H5.99、5.97分別與C-2、C-3相關，表明亞甲二氧基與C-2、C-3連接；4個甲氧基H3.61、3.78、3.84、3.88分別與C-14、C-1、C-13、C-12相關，確定了甲氧基的連接位置。綜上所述，化合物1的平面結構得以確定。

化合物1的立體結構利用CD光譜和ROESY譜來確定。文獻報道型聯苯環辛烯類木脂素的CD光譜在215～225 nm為正Cotton效應，在235～255 nm為負Cotton效應，而型的CD光譜則相反[15]。化合物1的實驗ECD光譜顯示在222 nm有正Cotton效應，在243 nm有負Cotton效應，表明1是型聯苯環辛烯類木脂素。同時，ROESY譜中（圖1）H-4/H-6、H-6/H-18相關，顯示H-4、H-6和H-18處于同側；H-11/H-8、H-8/H-9β相關，也顯示H-8、H-9β和H-11處于同側。最后，通過計算ECD和實驗ECD比較（圖2），確定其絕對構型為6、8。與已知化合物schiviridin A[15]的結構進行比對，二者苯環上的4個甲氧基和亞甲二氧基取代位置存在差異，且schiviridin A的絕對構型是6、8。因此，化合物1的結構鑒定為(a)-(5,7)- 5,6,7,8-四氫-1,11,12,13-四甲氧基-7-甲基-6-亞甲苯并[3,4]環辛基[1,2:4,5]苯并[1,2-f][1,3]二氧-5-基(2)-2-甲基-丁烯酸酯。經SciFinder檢索為未見文獻報道的新化合物，命名為綠葉五味子素B（schiviridin B）。

圖1 化合物1的結構及其主要1H-1H COSY、HMBC和ROESY相關信號

圖2 化合物1的計算ECD和實驗ECD圖譜

化合物2：白色晶體（甲醇）；[α]20 D?42.3°(0.052，MeOH)；C27H32O9；ESI-MS/: 523.25 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.86 (1H, s, H-4), 5.51 (1H, s, H-6), 2.00 (1H, m, H-8), 2.26 (1H, dd,= 14.1, 9.6 Hz, H-9β), 2.18 (1H, dd,= 14.1, 1.3 Hz, H-9α), 6.48 (1H, s, H-11), 1.14 (3H, d,= 7.1 Hz, H-17), 1.36 (3H, s, H-18), 5.95 (1H, m, H-3), 1.84 (3H, dq,= 7.3, 1.5 Hz, H-4), 1.42 (3H, d,= 1.5 Hz, H-5), 3.55 (3H, s, 1-OCH3), 3.93 (3H, s, 2-OCH3), 3.93 (3H, s, 3-OCH3), 5.97 (1H, d,= 1.4 Hz, 12, 13-OCH2O), 5.89 (1H, d,= 1.4 Hz, 12, 13-OCH2O), 5.15 (1H, s, 14-OH)；13C-NMR (100 MHz, CDCl3): 150.9 (C-1), 142.0 (C-2), 152.6 (C-3), 111.5 (C-4), 132.5 (C-5), 84.8 (C-6), 72.3 (C-7), 42.6 (C-8), 36.6 (C-9), 135.7 (C-10), 102.2 (C-11), 148.6 (C-12), 133.6 (C-13), 136.7 (C-14), 118.5 (C-15), 120.0 (C-16), 20.0 (C-17), 28.4 (C-18), 166.2 (C-1), 126.9 (C-2), 140.1 (C-3), 15.9 (C-4), 18.8 (C-5), 61.5 (1-OCH3), 61.3 (2-OCH3), 56.1 (3-OCH3), 101.4 (12, 13-OCH2O)。以上數據與文獻報道對比基本一致[16]，鑒定化合物2為sphaerandrin A。

化合物3：白色晶體（甲醇）；[α]20 D＋126.6°(0.064，MeOH)；C28H36O8；ESI-MS/: 501.25 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.55 (1H, s, H-4), 2.71 (1H, d,= 13.7 Hz, H-6α), 2.33 (1H, d,= 13.7 Hz, H-6β), 1.89 (1H, m, H-8), 2.69 (1H, dd,= 14.2, 1.8 Hz, H-9α), 2.41 (1H, dd,= 14.2, 7.6 Hz, H-9β), 6.68 (1H, s, H-11), 0.85 (3H, d,= 7.3 Hz, H-17), 1.24 (3H, s, H-18), 6.82 (1H, m, H-3), 1.71 (3H, overlapped, H-4), 1.69 (3H, overlapped, H-5), 3.50 (3H, s, 1-OCH3), 3.83 (3H, s, 2-OCH3), 3.87 (3H, s, 3-OCH3), 3.82 (3H, s, 13-OCH3), 3.90 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 152.0 (C-1), 140.5 (C-2), 152.6 (C-3), 110.3 (C-4), 133.2 (C-5), 40.8 (C-6), 72.1 (C-7), 42.1 (C-8), 34.4 (C-9), 133.9 (C-10), 112.9 (C-11), 142.8 (C-12), 140.0 (C-13), 151.8 (C-14), 123.3 (C-15), 123.1 (C-16), 16.0 (C-17), 30.0 (C-18), 165.9 (C-1), 128.1 (C-2), 138.3 (C-3), 12.2 (C-4), 14.5 (C-5), 61.0 (1-OCH3), 61.1 (2-OCH3), 56.2 (3-OCH3), 60.8 (13-OCH3), 56.2 (14-OCH3)。以上數據與文獻報道對比基本一致[17]，鑒定化合物3為sieverlignan E。

招聘需求人數規模度指標用來表征崗位的人數需求緊缺度，即崗位在同行業中的人數需求緊缺情況。計算方法是先對招聘需求實際人數進行修正，修正值為招聘需求人數和發布頻率的比值。招聘需求人數規模度指標為崗位招聘需求人數修正值和崗位所在細分領域內招聘需求人數修正值總和的比值。發布頻率指標用于表征崗位招聘需求在時間上的緊缺程度，意思是平均每家公司每天發布的崗位需求情況，計算方法是招聘發布公司數量和發布天數的乘積比招聘發布條數。

化合物4：白色晶體（甲醇）；[α]20 D?24.1°(0.058，MeOH)；C22H28O6；ESI-MS/: 411.36 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.37 (1H, s, H-4), 2.24 (1H, dd,= 13.3, 9.4 Hz, H-6β), 2.04 (1H, d,= 13.3 Hz, H-6α), 1.81 (1H, m, H-7), 1.89 (1H, m, H-8), 2.56 (1H, dd,= 13.5, 7.4 Hz, H-9β), 2.44 (1H, d,= 13.5, 1.9 Hz, H-9α), 6.66 (1H, s, H-11), 0.73 (3H, d,= 7.1 Hz, H-17), 1.00 (3H, d,= 7.1 Hz, H-18), 5.74 (1H, s, 1-OH), 3.87 (3H, s, 2-OCH3), 3.90 (3H, s, 3-OCH3), 5.68 (1H, s, 12-OH), 3.93 (3H, s, 13-OCH3), 3.60 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 146.7 (C-1), 133.5 (C-2), 151.9 (C-3), 104.0 (C-4), 140.0 (C-5), 35.6 (C-6), 41.0 (C-7), 33.9 (C-8), 38.9 (C-9), 135.5 (C-10), 113.8 (C-11), 147.9 (C-12), 137.7 (C-13), 150.3 (C-14), 121.6 (C-15), 115.9 (C-16), 12.6 (C-17), 22.0 (C-18), 61.2 (2-OCH3), 55.9 (3-OCH3), 61.2 (13-OCH3), 60.6 (14-OCH3)。以上數據與文獻報道對比基本一致[18]，鑒定化合物4為arisanschinin G。

化合物5：白色針晶（甲醇）；[α]20 D?82.6°(0.086，MeOH)；C15H22O2；ESI-MS/: 235.25 [M＋H]+。1H-NMR (400 MHz, CDCl3): 2.24 (2H, m, H-1), 7.10 (1H, m, H-2), 2.34 (1H, m, H-4a), 1.84 (1H, m, H-4b), 1.54 (2H, m, H-5), 1.78 (1H, m, H-8a), 1.19 (1H, m, H-8b), 2.08 (1H, m, H-9a), 1.41 (1H, m, H-9b), 2.16 (2H, m, H-10), 4.86 (1H, s, H-12a), 4.36 (1H, s, H-12b), 0.88 (3H, s, H-13), 0.85 (3H, s, H-14)；13C-NMR (100 MHz, CDCl3): 30.1 (C-1), 142.2 (C-2), 128.9 (C-3), 21.8 (C-4), 23.7 (C-5), 45.0 (C-6), 37.3 (C-7), 37.0 (C-8), 25.6 (C-9), 32.1 (C-10), 148.5 (C-11), 110.9 (C-12), 23.2 (C-13), 25.0 (C-14), 173.0 (C-15)。以上數據與文獻報道對比基本一致[19]，鑒定化合物5為widdaranal F。

化合物6：白色晶體（甲醇）；[α]20 D＋59.5°(0.074，MeOH)；C23H28O7；ESI-MS/: 439.26 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.61 (1H, s, H-4), 2.67 (1H, d,= 13.5 Hz, H-6α), 2.35 (1H, d,= 13.5 Hz, H-6β), 2.00 (1H, s, 7-OH), 1.85 (1H, m, H-8), 2.57 (1H, dd,= 14.1, 1.6 Hz, H-9α), 2.32 (1H, dd,= 14.1, 7.4 Hz, H-9β), 6.47 (1H, s, H-11), 0.81 (3H, d,= 7.3 Hz, H-17), 1.25 (3H, s, H-18), 3.51 (3H, s, 1-OCH3), 3.90 (3H, s, 2-OCH3), 3.91 (3H, s, 3-OCH3), 5.96 (2H, s, 12, 13-OCH2O), 3.83 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 152.2 (C-1), 140.8 (C-2), 152.4 (C-3), 110.4 (C-4), 132.1 (C-5), 40.6 (C-6), 71.7 (C-7), 42.1 (C-8), 33.8 (C-9), 132.6 (C-10), 106.1 (C-11), 148.0 (C-12), 135.0 (C-13), 141.3 (C-14), 121.9 (C-15), 124.2 (C-16), 15.9 (C-17), 30.2 (C-18), 60.7 (1-OCH3), 61.1 (2-OCH3), 56.1 (3-OCH3), 101.0 (12, 13-OCH2O), 59.8 (14-OCH3)。以上數據與文獻報道對比基本一致[20]，鑒定化合物6為gomisin A。

化合物7：白色晶體（甲醇）；[α]20 D?20.9°(0.067，MeOH)；C28H34O9；ESI-MS/: 537.35 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.76 (1H, s, H-4), 5.61 (1H, s, H-6), 1.93 (1H, m, H-8), 2.29 (1H, dd,= 14.0, 9.7 Hz, H-9β), 2.13 (1H, d,= 14.0 Hz, H-9α), 6.45 (1H, s, H-11), 1.12 (3H, d,= 7.1 Hz, H-17), 1.32 (3H, s, H-18), 5.99 (1H, m, H-3), 1.84 (3H, dq,= 7.3, 1.6 Hz, H-4), 1.38 (3H, q,= 1.6 Hz, H-5), 3.72 (3H, s, 1-OCH3), 3.88 (3H, s, 2-OCH3), 3.89 (3H, s, 3-OCH3), 5.89 (1H, d,= 1.4 Hz, 12, 13-OCH2O), 5.86 (1H, d,= 1.4 Hz, 12, 13-OCH2O), 3.55 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 152.2 (C-1), 141.8 (C-2), 152.0 (C-3), 109.9 (C-4), 130.7 (C-5), 84.5 (C-6), 72.3 (C-7), 42.5 (C-8), 36.5 (C-9), 135.3 (C-10), 102.8 (C-11), 148.8 (C-12), 134.3 (C-13), 140.6 (C-14), 121.3 (C-15), 122.3 (C-16), 19.1 (C-17), 28.2 (C-18), 166.0 (C-1), 127.2 (C-2), 140.1 (C-3), 15.8 (C-4), 19.9 (C-5), 60.8 (1-OCH3), 61.0 (2-OCH3), 55.9 (3-OCH3), 100.7 (12, 13-OCH2O), 59.2 (14-OCH3)。以上數據與文獻報道對比基本一致[21]，鑒定化合物7為gomisin B。

化合物8：白色晶體（甲醇）；[α]20 D?47.4°(0.076，MeOH)；C28H34O10；ESI-MS/: 553.36 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.79 (1H, s, H-4), 5.72 (1H, s, H-6), 1.76 (1H, m, H-8), 2.37 (1H, dd,= 14.1, 8.3 Hz, H-9β), 2.00 (1H, d,= 14.1 Hz, H-9α), 6.47 (1H, s, H-11), 1.05 (3H, d,= 7.0 Hz, H-17), 1.22 (3H, s, H-18), 1.65 (1H, m, H-21), 3.71 (2H, m, H-22), 1.28 (3H, s, H-23), 1.14 (3H, d,= 7.2 Hz, H-24), 3.56 (3H, s, 1-OCH3), 3.84 (3H, s, 2-OCH3), 3.91 (3H, s, 3-OCH3), 6.00 (1H, d,= 1.4 Hz, 12, 13-OCH2O), 5.91 (1H, d,= 1.4 Hz, 12, 13-OCH2O)；13C-NMR (100 MHz, CDCl3): 152.0 (C-1), 142.5 (C-2), 152.2 (C-3), 110.9 (C-4), 130.3 (C-5), 87.6 (C-6), 72.2 (C-7), 44.0 (C-8), 36.1 (C-9), 136.5 (C-10), 102.7 (C-11), 148.6 (C-12), 137.3 (C-13), 138.4 (C-14), 121.4 (C-15), 122.6 (C-16), 19.0 (C-17), 27.6 (C-18), 177.7 (C-19), 75.0 (C-20), 37.9 (C-21), 73.0 (C-22), 24.8 (C-23), 11.4 (C-24), 60.8 (1-OCH3), 60.9 (2-OCH3), 56.1 (3-OCH3), 101.2 (12, 13-OCH2O)。以上數據與文獻報道對比基本一致[22]，鑒定化合物8為gomisin D。

化合物9：白色晶體（甲醇）；[α]20 D?126.5°(0.068，MeOH)；C30H32O9；ESI-MS/: 559.25 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.77 (1H, s, H-4), 5.88 (1H, s, H-6), 2.13 (1H, m, H-8), 2.48 (1H, dd,= 14.0, 10.1 Hz, H-9β), 2.28 (1H, d,= 14.0 Hz, H-9α), 6.69 (1H, s, H-11), 1.20 (3H, d,= 7.0 Hz, H-17), 1.33 (3H, s, H-18), 7.36 (5H, overlapped, H-2～6), 3.39 (3H, s, 1-OCH3), 6.00 (2H, d,= 1.6 Hz, 2, 3-OCH2O), 3.98 (3H, s, 12-OCH3), 3.81 (3H, s, 13-OCH3), 3.14 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 141.8 (C-1), 137.2 (C-2), 148.2 (C-3), 107.4 (C-4), 128.9 (C-5), 84.5 (C-6), 72.6 (C-7), 42.3 (C-8), 36.9 (C-9), 136.6 (C-10), 106.3 (C-11), 153.4 (C-12), 140.0 (C-13), 150.8 (C-14), 122.4 (C-15), 121.9 (C-16), 19.1 (C-17), 28.4 (C-18), 164.9 (-CO), 129.6 (C-1), 129.3 (C-2, 6), 128.2 (C-3, 5), 133.3 (C-4), 60.0 (1-OCH3), 101.5 (2, 3-OCH2O), 56.2 (12-OCH3), 60.2 (13-OCH3), 59.8 (14-OCH3)。以上數據與文獻報道對比基本一致[21]，鑒定化合物9為gomisin G。

化合物10：白色晶體（甲醇）；[α]20 D?112.5°(0.056，MeOH)；C23H30O6；ESI-MS/: 403.30 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.54 (1H, s, H-4), 2.54 (2H, m, H-6), 1.84 (1H, overlapped, H-7), 1.84 (1H, overlapped, H-8), 2.22 (1H, dd,= 13.1, 9.4 Hz, H-9β), 2.01 (1H, dd,= 13.1, 1.3 Hz, H-9α), 6.62 (1H, s, H-11), 0.96 (3H, d,= 7.1 Hz, H-17), 0.72 (3H, d,= 7.1 Hz, H-18), 3.54 (3H, s, 1-OCH3), 3.88 (3H, s, 2-OCH3), 3.88 (3H, s, 3-OCH3), 5.86 (1H, s, 12-OH), 3.90 (3H, s, 13-OCH3), 3.55 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 151.6 (C-1), 140.1 (C-2), 151.6 (C-3), 110.6 (C-4), 134.2 (C-5), 39.3 (C-6), 33.8 (C-7), 40.9 (C-8), 35.3 (C-9), 140.1 (C-10), 110.1 (C-11), 148.8 (C-12), 137.4 (C-13), 150.3 (C-14), 121.5 (C-15), 123.3 (C-16), 21.8 (C-17), 12.7 (C-18), 60.6 (1-OCH3), 61.1 (2-OCH3), 56.0 (3-OCH3), 61.0 (13-OCH3), 60.2 (14-OCH3)。以上數據與文獻報道對比基本一致[20]，鑒定化合物10為(?)-gomisin K1。

化合物11：白色晶體（甲醇）；[α]20 D＋3.8°(0.053，MeOH)；C23H30O6；ESI-MS/: 403.31 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.54 (1H, s, H-4), 2.16 (2H, m, H-6), 1.84 (1H, overlapped, H-7), 1.84 (1H, overlapped, H-8), 2.51 (2H, m, H-9), 6.62 (1H, s, H-11), 0.73 (3H, d,= 7.1 Hz, H-17), 0.99 (3H, d,= 7.1 Hz, H-18), 3.55 (3H, s, 1-OCH3), 3.89 (3H, s, 2-OCH3), 3.92 (3H, s, 3-OCH3), 5.70 (1H, s, 12-OH), 3.88 (3H, s, 13-OCH3), 3.55 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 151.5 (C-1), 139.9 (C-2), 153.0 (C-3), 107.4 (C-4), 139.5 (C-5), 35.7 (C-6), 41.0 (C-7), 33.9 (C-8), 38.9 (C-9), 134.8 (C-10), 113.1 (C-11), 147.6 (C-12), 137.7 (C-13), 150.4 (C-14), 122.7 (C-15), 122.3 (C-16), 12.6 (C-17), 22.0 (C-18), 60.7 (1-OCH3), 61.1 (2-OCH3), 56.0 (3-OCH3), 61.1 (13-OCH3), 60.2 (14-OCH3)。以上數據與文獻報道對比基本一致[23]，鑒定化合物11為(＋)-gomisin K2。

化合物12：白色晶體（甲醇）；[α]20 D?5.9°(0.051，MeOH)；C22H26O6；ESI-MS/: 387.26 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.51 (1H, s, H-4), 2.51 (2H, m, H-6), 1.84 (1H, overlapped, H-7), 1.84 (1H, overlapped, H-8), 2.16 (2H, m, H-9), 6.37 (1H, s, H-11), 1.00 (3H, d,= 7.2 Hz, H-17), 0.73 (3H, d,= 7.2 Hz, H-18), 3.87 (3H, s, 1-OCH3), 5.95 (2H, d,= 1.6 Hz, 2, 3-OCH2O), 3.90 (3H, s, 12-OCH3), 3.90 (3H, s, 13-OCH3), 5.72 (1H, s, 14-OH)；13C-NMR (100 MHz, CDCl3): 141.3 (C-1), 135.1 (C-2), 148.0 (C-3), 106.6 (C-4), 133.2 (C-5), 39.1 (C-6), 34.0 (C-7), 40.9 (C-8), 35.5 (C-9), 140.1 (C-10), 104.0 (C-11), 151.8 (C-12), 133.2 (C-13), 146.8 (C-14), 115.8 (C-15), 121.4 (C-16), 22.1 (C-17), 12.4 (C-18), 59.9 (1-OCH3), 101.0 (2, 3-OCH2O), 55.8 (12-OCH3), 61.2 (13-OCH3)。以上數據與文獻報道對比基本一致[24]，鑒定化合物12為(?)-gomisin L1。

化合物13：白色晶體（甲醇）；[α]20 D＋3.2°(0.062，MeOH)；C22H26O6；ESI-MS/: 387.26 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.51 (1H, s, H-4), 2.14 (2H, m, H-6), 1.84 (1H, overlapped, H-7), 1.84 (1H, overlapped, H-8), 2.55 (2H, m, H-9), 6.38 (1H, s, H-11), 0.75 (3H, d,= 7.2 Hz, H-17), 0.97 (3H, d,= 7.2 Hz, H-18), 3.87 (3H, s, 1-OCH3), 5.95 (1H, d,= 1.5 Hz, 2, 3-OCH2O), 5.93 (1H, d,= 1.5 Hz, 2, 3-OCH2O), 3.91 (3H, s, 12-OCH3), 3.89 (3H, s, 13-OCH3), 5.72 (1H, s, 14-OH)；13C-NMR (100 MHz, CDCl3): 141.1 (C-1), 134.6 (C-2), 149.0 (C-3), 103.6 (C-4), 138.5 (C-5), 35.8 (C-6), 40.9 (C-7), 33.6 (C-8), 39.3 (C-9), 134.8 (C-10), 107.3 (C-11), 150.5 (C-12), 133.6 (C-13), 147.0 (C-14), 116.7 (C-15), 120.3 (C-16), 13.0 (C-17), 21.6 (C-18), 59.9 (1-OCH3), 100.9 (2, 3-OCH2O), 55.8 (12-OCH3), 61.1 (13-OCH3)。以上數據與文獻報道對比基本一致[25]，鑒定化合物13為(＋)-gomisin M1。

化合物14：白色晶體（甲醇）；[α]20 D?10.3°(0.078，MeOH)；C23H28O6；ESI-MS/: 401.25 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.55 (1H, s, H-4), 2.58 (1H, dd,= 13.6, 7.2 Hz, H-6β), 2.51 (1H, dd,= 13.6, 2.4 Hz, H-6α), 1.84 (1H, overlapped, H-7), 1.84 (1H, overlapped, H-8), 2.23 (1H, dd,= 13.3, 9.4 Hz, H-9β), 2.02 (1H, dd,= 13.3, 1.5 Hz, H-9α), 6.48 (1H, s, H-11), 0.99 (3H, d,= 7.2 Hz, H-17), 0.73 (3H, d,= 7.2 Hz, H-18), 3.54 (3H, s, 1-OCH3), 3.88 (3H, s, 2-OCH3), 3.89 (3H, s, 3-OCH3), 5.94 (2H, s, 12, 13-OCH2O), 3.82 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 151.7 (C-1), 140.1 (C-2), 151.7 (C-3), 110.7 (C-4), 134.2 (C-5), 39.2 (C-6), 33.9 (C-7), 40.8 (C-8), 35.6 (C-9), 137.9 (C-10), 103.0 (C-11), 148.8 (C-12), 134.6 (C-13), 141.2 (C-14), 121.4 (C-15), 123.4 (C-16), 21.7 (C-17), 12.9 (C-18), 60.6 (1-OCH3), 61.1 (2-OCH3), 56.0 (3-OCH3), 100.8 (12, 13-OCH2O), 59.7 (14-OCH3)。以上數據與文獻報道對比基本一致[26]，鑒定化合物14為gomisin N。

化合物15：白色晶體（甲醇）；[α]20 D＋2.2°(0.091，MeOH)；C28H36O8；ESI-MS/: 523.20 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.53 (1H, s, H-4), 2.71 (1H, d,= 13.7 Hz, H-6α), 2.30 (1H, d,= 13.7 Hz, H-6β), 1.84 (1H, m, H-8), 2.67 (1H, dd,= 14.6, 1.8 Hz, H-9α), 2.38 (1H, dd,= 14.6, 7.6 Hz, H-9β), 6.66 (1H, s, H-11), 0.81 (3H, d,= 7.3 Hz, H-17), 1.21 (3H, s, H-18), 5.85 (1H, m, H-3), 1.73 (3H, overlapped, H-4), 1.72 (3H, overlapped, H-5), 3.50 (3H, s, 1-OCH3), 3.80 (3H, s, 2-OCH3), 3.83 (3H, s, 3-OCH3), 3.87 (3H, s, 12-OCH3), 3.80 (3H, s, 13-OCH3)；13C-NMR (100 MHz, CDCl3): 151.7 (C-1), 140.3 (C-2), 152.6 (C-3), 110.1 (C-4), 133.1 (C-5), 40.7 (C-6), 72.0 (C-7), 41.9 (C-8), 34.3 (C-9), 133.9 (C-10), 112.8 (C-11), 151.8 (C-12), 139.7 (C-13), 142.3 (C-14), 123.2 (C-15), 122.9 (C-16), 15.9 (C-17), 29.9 (C-18), 165.6 (C-1), 127.6 (C-2), 137.3 (C-3), 15.3 (C-4), 20.3 (C-5), 60.6 (1-OCH3), 60.9 (2-OCH3), 56.0 (3-OCH3), 56.0 (12-OCH3), 60.8 (13-OCH3)。以上數據與文獻報道對比基本一致[20]，鑒定化合物15為angeloylgomisin H。

化合物16：白色晶體（甲醇）；[α]20 D＋20.8°(0.051，MeOH)；C28H34O8；ESI-MS/: 521.26 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.75 (1H, s, H-4), 5.75 (1H, d,= 8.5 Hz, H-6), 1.89 (1H, m, H-7), 1.89 (1H, m, H-8), 2.18 (2H, m, H-9), 6.40 (1H, s, H-11), 0.94 (3H, d,= 6.9 Hz, H-17), 0.83 (3H, d,= 6.9 Hz, H-18), 5.92 (1H, overlapped, H-3), 1.84 (3H, d,= 7.2 Hz, H-4), 1.57 (3H, s, H-5), 3.51 (3H, s, 1-OCH3), 3.88 (3H, s, 2-OCH3), 3.89 (3H, s, 3-OCH3), 5.92 (2H, m, 12, 13-OCH2O), 3.80 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 151.9 (C-1), 141.7 (C-2), 151.9 (C-3), 111.2 (C-4), 132.9 (C-5), 80.9 (C-6), 37.1 (C-7), 37.3 (C-8), 37.9 (C-9), 135.2 (C-10), 102.4 (C-11), 148.8 (C-12), 134.6 (C-13), 142.0 (C-14), 121.7 (C-15), 123.7 (C-16), 18.0 (C-17), 15.7 (C-18), 167.1 (C-1), 128.1 (C-2), 138.2 (C-3), 15.7 (C-4), 20.2 (C-5), 60.5 (1-OCH3), 61.0 (2-OCH3), 56.1 (3-OCH3), 100.1 (12, 13-OCH2O), 59.4 (14-OCH3)。以上數據與文獻報道對比基本一致[27]，鑒定化合物16為angeloylgomisin O。

化合物17：白色晶體（甲醇）；[α]20 D?8.8°(0.068，MeOH)；C29H38O9；ESI-MS/: 553.34 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.78 (1H, s, H-4), 5.73 (1H, s, H-6), 1.90 (1H, m, H-8), 2.33 (1H, dd,= 14.0, 9.8 Hz, H-9β), 2.18 (1H, d,= 14.0 Hz, H-9α), 6.53 (1H, s, H-11), 1.15 (3H, d,= 7.1 Hz, H-17), 1.31 (3H, s, H-18), 5.94 (1H, m, H-3), 1.80 (3H, dq,= 7.4, 1.7 Hz, H-4), 1.29 (3H, q,= 1.7 Hz, H-5), 3.50 (3H, s, 1-OCH3), 3.80 (3H, s, 2-OCH3), 3.88 (3H, s, 3-OCH3), 3.87 (3H, s, 12-OCH3), 3.86 (3H, s, 13-OCH3), 3.55 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 152.2 (C-1), 141.0 (C-2), 152.0 (C-3), 110.1 (C-4), 130.4 (C-5), 84.3 (C-6), 72.4 (C-7), 42.2 (C-8), 36.8 (C-9), 136.6 (C-10), 107.3 (C-11), 153.2 (C-12), 140.0 (C-13), 150.9 (C-14), 122.3 (C-15), 122.5 (C-16), 19.2 (C-17), 28.2 (C-18), 166.0 (C-1), 127.0 (C-2), 142.0 (C-3), 15.7 (C-4), 19.9 (C-5), 60.6 (1-OCH3), 60.9 (2-OCH3), 55.9 (3-OCH3), 56.2 (12-OCH3), 60.8 (13-OCH3), 60.3 (14-OCH3)。以上數據與文獻報道對比基本一致[28-29]，鑒定化合物17為angeloylgomisin Q。

化合物18：白色晶體（甲醇）；[α]20 D?115.9°(0.063，MeOH)；C31H36O9；ESI-MS/: 575.14 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.83 (1H, s, H-4), 5.97 (1H, s, H-6), 2.14 (1H, m, H-8), 2.48 (1H, dd,= 14.1, 10.0 Hz, H-9β), 2.28 (1H, d,= 14.1 Hz, H-9α), 6.68 (1H, s, H-11), 1.20 (3H, d,= 7.1 Hz, H-17), 1.34 (3H, s, H-18), 7.35 (5H, overlapped, H-2～6), 3.16 (3H, s, 1-OCH3), 3.57 (3H, s, 2-OCH3), 3.97 (3H, s, 3-OCH3), 3.89 (3H, s, 12-OCH3), 3.88 (3H, s, 13-OCH3), 3.38 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 152.3 (C-1), 142.1 (C-2), 152.0 (C-3), 110.3 (C-4), 130.1 (C-5), 84.5 (C-6), 72.6 (C-7), 42.4 (C-8), 36.9 (C-9), 136.5 (C-10), 107.2 (C-11), 153.2 (C-12), 140.1 (C-13), 150.7 (C-14), 122.5 (C-15), 122.6 (C-16), 19.1 (C-17), 28.2 (C-18), 165.0 (-CO), 129.3 (C-1), 129.6 (C-2, 6), 128.2 (C-3, 5), 133.3 (C-4), 60.2 (1-OCH3), 60.9 (2-OCH3), 56.0 (3-OCH3), 56.2 (12-OCH3), 60.8 (13-OCH3), 59.9 (14-OCH3)。以上數據與文獻報道對比基本一致[28]，鑒定化合物18為benzoylgomisin Q。

化合物19：白色晶體（甲醇）；[α]20 D＋87.1°(0.124，MeOH)；C24H32O7；ESI-MS/: 455.36 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.59 (1H, s, H-4), 2.63 (1H, d,= 13.4 Hz, H-6β), 2.34 (1H, d,= 13.4 Hz, H-6α), 1.97 (1H, s, 7-OH), 1.85 (1H, m, H-8), 2.57 (1H, dd,= 14.2, 1.8 Hz, H-9α), 2.35 (1H, dd,= 14.2, 7.7 Hz, H-9β), 6.51 (1H, s, H-11), 0.79 (3H, d,= 7.3 Hz, H-17), 1.23 (3H, s, H-18), 3.51 (3H, s, 1-OCH3), 3.85 (3H, s, 2-OCH3), 3.88 (3H, s, 3-OCH3), 3.86 (3H, s, 12-OCH3), 3.86 (3H, s, 13-OCH3), 3.56 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 151.8 (C-1), 140.7 (C-2), 152.4 (C-3), 110.4 (C-4), 131.9 (C-5), 40.8 (C-6), 71.8 (C-7), 41.8 (C-8), 34.2 (C-9), 133.9 (C-10), 110.0 (C-11), 152.0 (C-12), 140.1 (C-13), 151.6 (C-14), 124.2 (C-15), 122.7 (C-16), 15.9 (C-17), 29.9 (C-18), 60.7 (1-OCH3), 61.0 (2-OCH3), 56.0 (3-OCH3), 55.9 (12-OCH3), 61.0 (13-OCH3), 60.6 (14-OCH3)。以上數據與文獻報道對比一致[20]，鑒定化合物19為schisandrin。

化合物20：白色針晶（甲醇）；[α]20 D＋9.3°(0.086，MeOH)；C24H32O6；ESI-MS/: 417.36 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.55 (1H, s, H-4), 2.59 (1H, dd,= 13.5 , 7.3 Hz, H-6β), 2.06 (1H, d,= 13.5 Hz, H-6α), 1.85 (1H, overlapped, H-7), 1.85 (1H, overlapped, H-8), 2.50 (1H, d,= 13.2 Hz, H-9α), 2.28 (1H, dd,= 13.2 , 9.5 Hz, H-9β), 6.54 (1H, s, H-11), 0.74 (3H, d,= 7.1 Hz, H-17), 1.00 (3H, d,= 7.1 Hz, H-18), 3.59 (3H, s, 1-OCH3), 3.87 (3H, s, 2-OCH3), 3.89 (3H, s, 3-OCH3), 3.88 (3H, s, 12-OCH3), 3.88 (3H, s, 13-OCH3), 3.59 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 151.4 (C-1), 139.9 (C-2), 152.7 (C-3), 107.0 (C-4), 139.0 (C-5), 35.4 (C-6), 40.6 (C-7), 33.6 (C-8), 39.0 (C-9), 133.8 (C-10), 110.3 (C-11), 151.5 (C-12), 139.6 (C-13), 151.3 (C-14), 123.2 (C-15), 122.2 (C-16), 12.5 (C-17), 21.7 (C-18), 60.4 (1-OCH3), 60.8 (2-OCH3), 55.7 (3-OCH3), 55.7 (12-OCH3), 60.8 (13-OCH3), 60.4 (14-OCH3)。以上數據與文獻報道對比基本一致[20]，鑒定化合物20為schisandrin A。

化合物21：白色晶體（甲醇）；[α]20 D0°(0.084，MeOH)；C23H28O6；ESI-MS/: 401.30 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.54 (1H, s, H-4), 2.31 (1H, dd,= 13.2, 9.6 Hz, H-6β), 2.04 (1H, dd,= 13.2, 1.5 Hz, H-6α), 1.83 (1H, overlapped, H-7), 1.83 (1H, overlapped, H-8), 2.55 (1H, dd,= 13.5, 7.3 Hz, H-9β), 2.43 (1H, dd,= 13.5, 1.8 Hz, H-9α), 6.48 (1H, s, H-11), 0.73 (3H, dd,= 7.1 Hz, H-17), 0.99 (3H, d,= 7.1 Hz, H-18), 3.54 (3H, s, 1-OCH3), 3.88 (3H, s, 2-OCH3), 3.89 (3H, s, 3-OCH3), 5.95 (1H, d,= 1.4 Hz, 12, 13-OCH2O), 5.94 (1H, d,= 1.4 Hz, 12, 13-OCH2O), 3.83 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 151.5 (C-1), 139.8 (C-2), 152.9 (C-3), 107.5 (C-4), 139.5 (C-5), 35.5 (C-6), 40.8 (C-7), 33.9 (C-8), 38.9 (C-9), 132.6 (C-10), 106.0 (C-11), 147.7 (C-12), 134.9 (C-13), 141.3 (C-14), 122.3 (C-15), 122.5 (C-16), 12.5 (C-17), 22.1 (C-18), 60.7 (1-OCH3), 61.1 (2-OCH3), 55.9 (3-OCH3), 100.8 (12, 13-OCH2O), 59.7 (14-OCH3)。以上數據與文獻報道對比基本一致[24]，鑒定化合物21為γ-schisandrin。

化合物22：白色固體（甲醇）；[α]20 D?8.7°(0.072，MeOH)；C22H24O6；ESI-MS/: 385.32 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.48 (1H, s, H-4), 2.54 (1H, dd,= 13.6, 7.2 Hz, H-6β), 2.44 (1H, dd,= 13.6, 1.9 Hz, H-6α), 1.82 (1H, m, H-7), 1.82 (1H, m, H-8), 2.24 (1H, dd,= 13.2 , 9.5 Hz, H-9β), 2.00 (1H, d,= 13.2 Hz, H-9α), 6.48 (1H, s, H-11), 0.96 (3H, d,= 7.2 Hz, H-17), 0.73 (3H, d,= 7.2 Hz, H-18), 3.82 (3H, s, 1-OCH3), 5.94 (2H, overlapped, 2, 3-OCH2O), 5.94 (2H, overlapped, 12, 13-OCH2O), 3.83 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 141.4 (C-1), 134.8 (C-2), 147.7 (C-3), 106.2 (C-4), 132.9 (C-5), 38.9 (C-6), 33.7 (C-7), 40.8 (C-8), 35.4 (C-9), 138.3 (C-10), 103.3 (C-11), 148.8 (C-12), 134.5 (C-13), 141.1 (C-14), 121.1 (C-15), 122.3 (C-16), 21.9 (C-17), 12.7 (C-18), 59.8 (1-OCH3), 100.8 (2, 3-OCH2O), 100.8 (12, 13-OCH2O), 59.8 (14-OCH3)。以上數據與文獻報道對比基本一致[30]，故鑒定化合物22為schisandrin C。

化合物23：白色晶體（甲醇）；[α]20 D?150.0°(0.056，MeOH)；C28H34O9；ESI-MS/: 537.28 [M＋Na]+。1H-NMR (400 MHz, CDCl3): 6.76 (1H, s, H-4), 5.67 (1H, s, H-6), 1.95 (1H, m, H-8), 2.30 (1H, dd,= 14.0, 9.7 Hz, H-9β), 2.15 (1H, d,= 14.0 Hz, H-9α), 6.50 (1H, s, H-11), 1.13 (3H, d,= 7.0 Hz, H-17), 1.30 (3H, s, H-18), 6.01 (1H, m, H-3), 1.67 (3H, d,= 7.0 Hz, H-4), 1.56 (3H, s, H-5), 3.55 (3H, s, 1-OCH3), 3.86 (3H, s, 2-OCH3), 3.88 (3H, s, 3-OCH3), 5.92 (1H, d,= 1.4 Hz, 12, 13-OCH2O), 5.86 (1H, d,= 1.4 Hz, 12, 13-OCH2O), 3.68 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 152.0 (C-1), 141.8 (C-2), 152.2 (C-3), 110.1 (C-4), 130.9 (C-5), 84.3 (C-6), 72.3 (C-7), 42.5 (C-8), 36.5 (C-9), 137.6 (C-10), 102.7 (C-11), 148.7 (C-12), 134.4 (C-13), 140.7 (C-14), 121.5 (C-15), 122.2 (C-16), 19.0 (C-17), 28.2 (C-18), 166.3 (C-1), 127.7 (C-2), 135.4 (C-3), 14.4 (C-4), 11.6 (C-5), 60.8 (1-OCH3), 61.0 (2-OCH3), 56.0 (3-OCH3), 100.6 (12, 13-OCH2O), 59.1 (14-OCH3)。以上數據與文獻報道對比基本一致[31]，鑒定化合物23為schisantherin C。

化合物24：白色晶體（甲醇）；[α]20 D?13.5°(0.052，MeOH)；C22H26O6；ESI-MS/: 387.26 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.63 (1H, s, H-4), 2.25 (1H, dd,= 13.2, 9.4 Hz, H-6β), 2.00 (1H, d,= 13.2 Hz, H-6α), 1.83 (1H, overlapped, H-7), 1.83 (1H, overlapped, H-8), 2.55 (1H, dd,= 13.6, 7.3 Hz, H-9β), 2.44 (1H, dd,= 13.6, 1.8 Hz, H-9α), 6.49 (1H, s, H-11), 0.73 (3H, d,= 7.1 Hz, H-17), 0.97 (3H, d,= 7.1 Hz, H-18), 3.50 (3H, s, 1-OCH3), 3.93 (3H, s, 2-OCH3), 5.70 (1H, s, 3-OH), 5.96 (2H, d,= 1.4 Hz, 12, 13-OCH2O), 3.78 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 150.4 (C-1), 137.5 (C-2), 148.8 (C-3), 110.3 (C-4), 140.4 (C-5), 35.2 (C-6), 41.0 (C-7), 33.9 (C-8), 39.1 (C-9), 132.8 (C-10), 106.3 (C-11), 147.8 (C-12), 135.2 (C-13), 141.4 (C-14), 121.6 (C-15), 122.6 (C-16), 12.5 (C-17), 22.0 (C-18), 60.3 (1-OCH3), 61.2 (2-OCH3), 100.9 (12, 13-OCH2O), 59.8 (14-OCH3)。以上數據與文獻報道對比基本一致[32]，鑒定化合物24為neglschisandrin E。

化合物25：黃色粉末（甲醇）；[α]20 D＋117.9°(0.056，MeOH)；C24H30O6；ESI-MS/: 415.30 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.65 (1H, s, H-4), 3.00 (1H, d,= 12.3 Hz, H-6β), 2.93 (1H, d,= 12.3 Hz, H-6α), 2.70 (1H, m, H-8), 2.54 (2H, m, H-9), 6.55 (1H, s, H-11), 1.01 (3H, d,= 7.2 Hz, H-17), 4.86 (1H, d,= 2.0 Hz, H-18a), 4.72 (1H, d,= 2.0 Hz, H-18b), 3.60 (3H, s, 1-OCH3), 3.86 (3H, s, 2-OCH3), 3.90 (3H, s, 3-OCH3), 3.89 (3H, s, 12-OCH3), 3.89 (3H, s, 13-OCH3), 3.62 (3H, s, 14-OCH3)；13C-NMR (100 MHz, CDCl3): 151.4 (C-1), 140.3 (C-2), 153.1 (C-3), 107.1 (C-4), 136.6 (C-5), 37.2 (C-6), 154.0 (C-7), 38.7 (C-8), 37.9 (C-9), 133.3 (C-10), 110.5 (C-11), 152.0 (C-12), 140.5 (C-13), 151.6 (C-14), 123.8 (C-15), 122.6 (C-16), 20.7 (C-17), 111.0 (C-18), 60.7 (1-OCH3), 61.1 (2-OCH3), 56.0 (3-OCH3), 56.1 (12-OCH3), 61.1 (13-OCH3), 60.7 (14-OCH3)。以上數據與文獻報道對比基本一致[33]，鑒定化合物25為7(18)-dehydroschisandro A。

化合物26：棕色油狀物（甲醇）；[α]20 D+11.5°(0.096，MeOH)；C20H24O4；ESI-MS/: 329.20 [M＋H]+。1H-NMR (400 MHz, CDCl3): 6.62 (1H, d,= 1.9 Hz, H-2), 6.83 (1H, d,= 7.9 Hz, H-5), 6.63 (1H, dd,= 7.9, 1.9 Hz, H-6), 2.74 (1H, dd,= 13.6, 6.0 Hz, H-7a), 2.24 (1H, dd,= 13.6, 9.1 Hz, H-7b), 1.73 (1H, overlapped, H-8), 0.84 (3H, d,= 6.8 Hz, H-9), 3.87 (3H, s, 3-OCH3), 5.45 (1H, s, 4-OH), 6.65 (1H, d,= 1.7 Hz, H-2), 6.73 (1H, d,= 7.9 Hz, H-5), 6.60 (1H, dd,= 7.9, 1.7 Hz, H-6), 2.70 (1H, dd,= 13.2, 6.4 Hz, H-7a), 2.29 (1H, dd,= 13.2, 9.1 Hz, H-7b), 1.73 (1H, overlapped, H-8), 0.82 (3H, d,= 6.8 Hz, H-9), 5.92 (2H, s, 3, 4-OCH2O)；13C-NMR (100 MHz, CDCl3): 133.9 (C-1), 111.5 (C-2), 146.4 (C-3), 143.7 (C-4), 114.1 (C-5), 121.8 (C-6), 39.0 (C-7), 39.4 (C-8), 16.4 (C-9), 56.0 (3-OCH3), 135.8(C-1), 109.5 (C-2), 147.6 (C-3), 145.6 (C-4), 108.1 (C-5), 121.8 (C-6), 39.2 (C-7), 39.5 (C-8), 16.3 (C-9), 100.9 (3, 4-OCH2O)。以上數據與文獻報道對比基本一致[34]，鑒定化合物26為anwulignan。

4 討論

近年來課題組對蘇黃止咳膠囊改善氣道重塑[35]、痰阻塞[36]、抑制炎癥反應[37]、以及治療CVA[38-39]和PIC[40]等方面的藥理機制進行了闡釋，其功效成分及機制正在研究中。本研究作為該項目的一部分，進一步豐富了其臣藥五味子化學成分的多樣性，為后續開展蘇黃止咳膠囊的藥效物質基礎研究及其質量控制奠定了基礎。

利益沖突 所有作者均聲明不存在利益沖突

[1] 中國藥典[S]. 一部. 2020: 68.

[2] Zhou Y, Men L H, Sun Y X,. Pharmacodynamic effects and molecular mechanisms of lignans fromTurcz. (Baill.), a current review [J]., 2021, 892: 173796-173807.

[3] 陳麗華, 許智瑩, 林程程, 等. 五味子木脂素舒張大鼠離體氣管平滑肌的功能研究 [J]. 西北農林科技大學學報: 自然科學版, 2021, 49(10): 24-29.

[4] 孫靖輝, 呂希, 王春梅, 等. 五味子木脂素對哮喘模型小鼠Th2相關炎癥因子的影響 [J]. 北華大學學報: 自然科學版, 2020, 21(3): 325-328.

[5] Zhong S, Nie Y C, Gan Z Y,. Effects ofextracts on cough and pulmonary inflammation in a cough hypersensitivity guinea pig model induced by cigarette smoke exposure [J]., 2015, 165: 73-82.

[6] 林豪, 王闊, 曾欽成, 等. 基于網絡藥理學和分子對接技術探討五味子治療慢性咳嗽的機制研究 [J]. 北華大學學報: 自然科學版, 2022, 23(4): 466-470.

[7] 趙紅舟, 龍杞, 劉肇恒, 等. 五味子乙素對博來霉素誘導小鼠肺纖維化的干預作用及機制研究 [J]. 環球中醫藥, 2021, 14(4): 556-561.

[8] 魏菲, 劉斌, 肖娜, 等. 五味子乙素減輕博萊霉素誘導的肺纖維化 [J]. 天津中醫藥大學學報, 2017, 36(3): 200-204.

[9] Zhong S, Bai L P, Liu X D,. Cough inhibition activity ofin guinea pigs [J]., 2021, 24(4): 348-357.

[10] Lv X, Xu Z Y, Xu G Y,. Investigation of the active components and mechanisms ofin the treatment of asthma based on a network pharmacology approach and experimental validation [J]., 2020, 11(4): 3032-3042.

[11] Kim H, Ahn Y T, Kim Y S,. Antiasthmatic effects of schizandrae fructus extract in mice with asthma [J]., 2014, 10(Suppl 1): S80-S85.

[12] 李舒豐, 劉芹燕, 劉文東, 等. 蘇黃止咳膠囊及其揮發油中間體中揮發性成分的分析 [J]. 中成藥, 2017, 39(11): 2329-2334.

[13] 劉芹燕, 巫興東, 陳東, 等. 蘇黃止咳膠囊中非揮發性成分的LC-MS分析 [J]. 中成藥, 2019, 41(6): 1434-1445.

[14] Wu X D, Liu Q Y, Chen D,. Identification of quality control markers in Suhuang antitussive capsule based on HPLC-PDA fingerprint and anti-inflammatory screening [J]., 2020, 180: 113053-113061.

[15] Tian T, Liu Y, Yu H Y,. Dibenzocyclooctadiene lignans from the fruits of[J]., 2015, 51(6): 1046-1048.

[16] Ying Y M, Yu H F, Rao G W,. Dibenzocyclooctadiene lignans from the stems of[J]., 2022, 36(1): 287-294.

[17] Zhou X D, Chen C X, Zheng X K,. Dibenzocyclooctadiene lignans fromand their anti-inflammatory activities [J]., 2021, 75(4): 1014-1020.

[18] Cheng Y B, Chang M T, Lo Y W,. Oxygenated lignans from the fruits of[J]., 2009, 72(9): 1663-1668.

[19] Amujuri D, Siva B, Bharathi K,. Bio-active constituents from: Isolation, semi-synthesis and evaluation of their anticancer activities [J]., 2021, 45: 184-189.

[20] Choi S K, Lee Y G, Wang R B,. Dibenzocyclooctadiene lignans from the fruits ofand their cytotoxicity on human cancer cell lines [J]., 2020, 63(1): 1-8.

[21] Ikeya Y, Taguchi H, Yosioka I,. The constituents ofBaill. I. Isolation and structure determination of five new lignans, gomisin A, B, C, F and G, and the absolute structure of schizandrin [J]., 1979, 27(6): 1383-1394.

[22] 劉俊霞, 竇鳳鳴, 王英平. 五味子藤莖中木脂素類化合物的殺蟲活性成分研究 [J]. 天然產物研究與開發, 2017, 29(7): 1210-1217.

[23] Ikeya Y, Taguchi H, Yosioka I. The constituents ofBaill. VII. The structures of three new lignans, (?)-gomisin K1and (+)-gomisins K2and K3[J]., 1980, 28(8): 2422-2427.

[24] Ikeya Y, Taguchi H, Yosioka I. The Constituents ofBaill. X. The structures of GAMMA - schizandrin and four new lignans, (?)-gomisins L1 and L2, (±)-gomisin M1 and (+)-gomisin M2 [J]., 1982, 30(1): 132-139.

[25] Rui T, Lian-Niang L, Qicheng F. Studies on the chemical constituents of: Isolation and structure elucidation of five new lignans [J]., 1984, 50(5): 414-417.

[26] Piao L Z, Lee Y J, PhamPhu T T,. Dibenzocyclooctene lignan compounds isolated from the fruits ofBaill [J]., 2005, 11(4): 248-252.

[27] Ikeya Y, Ookawa N, Taguchi H,. The constituents ofBaill. XI. The structures of three new lignans, angeloylgomisin O, and angeloyl- and benzoylisogomisin O [J]., 1982, 30(9): 3202-3206.

[28] Ikeya Y, Miki E, Okada M,. Benzoylgomisin Q and benzoylgomisin P, two new lignans fromRehd. et Wils [J]., 1990, 38(5): 1408-1411.

[29] Ikeya Y, Taguchi H, Yosioka I. The constituents ofBaill. The cleavage of the methylenedioxy moiety with lead tetraacetate in benzene, and the structure of angeloylgomisin Q [J]., 1979, 27(10): 2536-2538.

[30] Yan Z F, Guo J, Tian F H,. Active compounds fromexhibiting tyrosinase activity and melanin content inhibition in B16 melanoma cells [J]., 2015, 20(4): 814-823.

[31] Smejkal K, Slapetová T, Krmen?ík P,. Evaluation of cytotoxic activity oflignans [J]., 2010, 76(15): 1672-1677.

[32] Chen M, Xu X M, Xu B,. Neglschisandrins E-F: Two new lignans and related cytotoxic lignans from[J]., 2013, 18(2): 2297-2306.

[33] Song Z H, Houa Y, Han N,. Research on the biotransformation of fourlignans [J]., 2015, 10(6): 129-133.

[34] Baek N I, Lee Y G, Wang R B,. Anwulignan from the fruits ofand its cytotoxicity against human cancer cell lines [J]., 2020, 16(72): 695-699.

[35] 郭超, 童希洋, 秦偉偉, 等. 蘇黃止咳膠囊改善哮喘豚鼠氣道重塑的作用及其機制 [J]. 中成藥, 2021, 43(4): 893-901.

[36] Tong X Y, Liang R Y, Jia Y N,. Suhuang antitussive capsules-ameliorative effects on LPS-induced sputum obstruction in mice through promoting HGF secretion [J]., 2019, 10: 1422-1436.

[37] Qin W W, Tong X Y, Liang R Y,. Preservation of mitochondrial homeostasis is responsible for the ameliorative effects of Suhuang antitussive capsule on non-resolving inflammation via inhibition of NF-κB signaling and NLRP3 inflammasome activation [J]., 2021, 271: 113827-113844.

[38] Qin W W, Wu X D, Jia Y N,. Suhuang antitussive capsule inhibits NLRP3 inflammasome activation and ameliorates pulmonary dysfunction via suppression of endoplasmic reticulum stress in cough variant asthma [J]., 2019, 118: 109188-109202.

[39] Jiang H, Bai Z Y, Ou Y Y,. β-Hydroxybutyric acid upregulated by Suhuang antitussive capsule ameliorates cough variant asthma through GSK3β/AMPK-Nrf2 signal axis [J]., 2023, 307: 116013-116025.

[40] Liang R Y, Tong X Y, Dong Z K,. Suhuang antitussive capsule ameliorates post-infectious cough in mice through AhR-Nrf2 pathway [J]., 2022, 283: 114664-114676.

A new dibenzocyclooctadiene lignan from

DI Tong-lian1, LIU Xiao-qing2, WU Nan1, CHEN Xiao-yuan1, FAN Jun-ting3, TAN Ning-hua1

1. School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China 2. Beijing Haiyan Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group, Beijing 102206, China 3. School of Pharmacy, Nanjing Medical University, Nanjing 211116, China

To study the lignans in.The petroleum ether extract mainly contained lignans ofwas isolated and purified by silica gel column chromatography, medium pressure reversed phase column chromatography, semi-prepared and prepared liquid chromatography. The structures of compounds were identified by spectral data.Twenty-six compounds were obtained, in which 24 were dibenzocyclooctadiene lignans. They were identified as schiviridin B (1), sphaerandrin A (2), sieverlignan E (3), arisanschinin G (4), widdaranal F (5), gomisin A (6), gomisin B (7), gomisin D (8), gomisin G (9), (?)-gomisin K1(10), (＋)-gomisin K2(11), (?)-gomisin L1(12), (＋)-gomisin M1(13), gomisin N (14), angeloylgomisin H (15), angeloylgomisin O (16), angeloylgomisin Q (17), benzoylgomisin Q (18), schisandrin (19), schisandrin A (20), γ-schisandrin (21), schisandrin C (22), schisantherin C (23), neglschisandrin E (24), 7(18)-dehydroschisandro A (25), and anwulignan (26).Compound 1 is new and compounds 2—5 are isolated from this plant for the first time.

(Turcz.) Baill.; schiviridin B; dibenzocyclooctadiene lignans; sphaerandrin A; sieverlignan E; arisanschinin G; widdaranal F; schisandrin

R284.1

A

0253 - 2670(2023)12 - 3759 - 12

10.7501/j.issn.0253-2670.2023.12.002

2023-04-02

國家自然科學基金項目（32070356）

邸同蓮，女，碩士研究生，研究方向為中藥物質基礎和質量控制研究。E-mail: 1282046265@qq.com

通信作者：譚寧華，教授，博士生導師，主要從事含環肽中藥和止咳中藥系統研究。E-mail: nhtan@cpu.edu.cn

范君婷，副教授，主要從事天然藥物化學與作用機制研究。E-mail: juntingfan@njmu.edu.cn

[責任編輯 王文倩]